0.3637
price up icon1.22%   0.0044
after-market Handel nachbörslich: .37 0.0063 +1.73%
loading
Schlusskurs vom Vortag:
$0.3593
Offen:
$0.36
24-Stunden-Volumen:
978.20K
Relative Volume:
0.36
Marktkapitalisierung:
$45.33M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-0.2425
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
+11.53%
1M Leistung:
-0.60%
6M Leistung:
-31.05%
1J Leistung:
-81.81%
1-Tages-Spanne:
Value
$0.345
$0.3678
1-Wochen-Bereich:
Value
$0.321
$0.3777
52-Wochen-Spanne:
Value
$0.2589
$2.83

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name
Firmenname
Mersana Therapeutics Inc
Name
Telefon
617-498-0020
Name
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Name
Mitarbeiter
102
Name
Twitter
@MersanaADC
Name
Nächster Verdiensttermin
2025-03-03
Name
Neueste SEC-Einreichungen
Name
MRSN's Discussions on Twitter

Vergleichen Sie MRSN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MRSN
Mersana Therapeutics Inc
0.3637 40.64M 36.86M -171.67M -171.05M -1.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-06 Eingeleitet William Blair Outperform
2024-11-15 Fortgesetzt Citigroup Buy
2024-03-19 Hochstufung JP Morgan Underweight → Neutral
2024-02-29 Hochstufung BTIG Research Neutral → Buy
2024-02-29 Hochstufung Guggenheim Neutral → Buy
2024-02-29 Hochstufung Wedbush Neutral → Outperform
2023-12-04 Hochstufung Citigroup Neutral → Buy
2023-07-28 Herabstufung Robert W. Baird Outperform → Neutral
2023-07-27 Herabstufung BTIG Research Buy → Neutral
2023-07-27 Herabstufung Citigroup Buy → Neutral
2023-07-27 Herabstufung Guggenheim Buy → Neutral
2023-07-27 Herabstufung JP Morgan Neutral → Underweight
2023-07-27 Herabstufung Truist Buy → Hold
2023-07-27 Herabstufung Wedbush Outperform → Neutral
2023-06-16 Herabstufung JP Morgan Overweight → Neutral
2023-06-15 Eingeleitet Guggenheim Buy
2023-03-16 Hochstufung JP Morgan Neutral → Overweight
2023-01-20 Eingeleitet Citigroup Buy
2022-11-21 Eingeleitet Truist Buy
2021-10-15 Fortgesetzt BTIG Research Buy
2021-08-30 Eingeleitet H.C. Wainwright Buy
2021-03-31 Eingeleitet Credit Suisse Neutral
2020-12-03 Eingeleitet Stifel Buy
2020-09-29 Fortgesetzt JP Morgan Neutral
2020-04-29 Eingeleitet BTIG Research Buy
2020-01-21 Bestätigt H.C. Wainwright Buy
2019-03-11 Herabstufung JP Morgan Neutral → Underweight
2018-11-14 Hochstufung Leerink Partners Mkt Perform → Outperform
2018-05-08 Eingeleitet Robert W. Baird Outperform
2018-03-19 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Mersana Therapeutics Inc. stock priceHigh-octane financial growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Mersana Therapeutics Inc. stock attracts strong analyst attentionFree Group Entry - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Mersana Therapeutics Inc. Stock Analysis and ForecastSuperior return velocity - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Mersana Therapeutics Inc. a good long term investmentExponential return rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Mersana Therapeutics Inc. stockHigh-impact investment strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Mersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Mersana Therapeutics Inc. stock price move sharplyTop Performing Low Risk Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Mersana Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Wealth Enhancement Advisory Services LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jul 11, 2025
pulisher
Jul 05, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Mersana Therapeutics Settles Debt with Oxford Finance - TipRanks

Jul 03, 2025
pulisher
Jul 01, 2025

Biotech layoff tracker: 18 companies cut 1,300 jobs in Q2 2025 - The Business Journals

Jul 01, 2025
pulisher
Jun 27, 2025

Mersana Therapeutics (MRSN) Plunges 5.23% Amid Drug Trial Data - AInvest

Jun 27, 2025
pulisher
Jun 15, 2025

94,531 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Pallas Capital Advisors LLC - Defense World

Jun 15, 2025
pulisher
Jun 13, 2025

Mersana Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st

Jun 11, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Has $302,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace

Jun 10, 2025
pulisher
Jun 10, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jun 10, 2025
pulisher
Jun 07, 2025

LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛

Jun 07, 2025
pulisher
Jun 06, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Nuveen Asset Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Sells 36,084 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 21.4% in May - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at William Blair - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Mersana reports promising Phase 1 ADC trial results By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Mersana reports promising Phase 1 ADC trial results - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

Mersana Therapeutics Reports Additional Positive Interim Phase 1 - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data for Cancer Treatment | MRSN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics Reports Encouraging Interim Phase 1 Results for Emiltatug Ledadotin in B7-H4 High Tumors at ASCO 2025 - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics Reports Additional Positive Interim - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in ... - Eagle-Tribune

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - Yahoo Finance

Jun 02, 2025

Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):